HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
HDAC6 抑制释放 HR23B 以激活蛋白酶体、扩大肿瘤免疫肽组并增强 T 细胞抗骨髓瘤活性
阅读：6
作者：Priyanka S Rana #, James J Ignatz-Hoover #, Byung-Gyu Kim #, Ehsan Malek, Yuriy Federov, Drew Adams, Timothy Chan, James J Driscoll
Significance
The elimination of therapy-resistant tumor cells remains a major challenge in the treatment of multiple myeloma. Our study identifies and functionally validates agents that amplify MHC class I-presented antigens and pave the way for the development of proteasome activators as immune adjuvants to enhance immunotherapeutic responses in patients with multiple myeloma.
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。
2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。
4、投稿及合作请联系：info@biocloudy.com。
